IL146105A - 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor - Google Patents

5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor

Info

Publication number
IL146105A
IL146105A IL14610500A IL14610500A IL146105A IL 146105 A IL146105 A IL 146105A IL 14610500 A IL14610500 A IL 14610500A IL 14610500 A IL14610500 A IL 14610500A IL 146105 A IL146105 A IL 146105A
Authority
IL
Israel
Prior art keywords
pyridyl
producing
same
azole compounds
use therefor
Prior art date
Application number
IL14610500A
Other languages
English (en)
Other versions
IL146105A0 (en
Original Assignee
Tadeda Pharmaceutical Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tadeda Pharmaceutical Company filed Critical Tadeda Pharmaceutical Company
Publication of IL146105A0 publication Critical patent/IL146105A0/xx
Publication of IL146105A publication Critical patent/IL146105A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
IL14610500A 1999-04-23 2000-04-20 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor IL146105A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP11668699 1999-04-23
JP22465099 1999-08-06
PCT/JP2000/002575 WO2000064894A1 (fr) 1999-04-23 2000-04-20 Composes 5-pyridyle-1,3-azole, leur procede de fabrication et leur utilisation

Publications (2)

Publication Number Publication Date
IL146105A0 IL146105A0 (en) 2002-07-25
IL146105A true IL146105A (en) 2005-09-25

Family

ID=26454974

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14610500A IL146105A (en) 1999-04-23 2000-04-20 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor

Country Status (24)

Country Link
US (3) US7101899B1 (zh)
EP (1) EP1180518B1 (zh)
KR (2) KR100449215B1 (zh)
CN (1) CN1156471C (zh)
AU (1) AU765473B2 (zh)
BR (1) BR0009952A (zh)
CA (1) CA2370264A1 (zh)
CZ (1) CZ300709B6 (zh)
DE (1) DE60033028T2 (zh)
DK (1) DK1180518T3 (zh)
ES (1) ES2275500T3 (zh)
HK (1) HK1044338B (zh)
HU (1) HUP0203766A3 (zh)
IL (1) IL146105A (zh)
MX (1) MXPA01010675A (zh)
MY (1) MY126736A (zh)
NO (1) NO320588B1 (zh)
NZ (1) NZ515215A (zh)
PL (1) PL351148A1 (zh)
PT (1) PT1180518E (zh)
RU (1) RU2237062C2 (zh)
SI (1) SI1180518T1 (zh)
SK (1) SK286666B6 (zh)
WO (1) WO2000064894A1 (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101899B1 (en) * 1999-04-23 2006-09-05 Takeda Pharmaceutical Company Limited 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
ATE311385T1 (de) 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
AU2001244618A1 (en) * 2000-03-30 2001-10-15 Takeda Chemical Industries Ltd. Substituted 1,3-thiazole compounds, their production and use
AU2002221080A1 (en) 2000-12-08 2002-06-18 Masami Kusaka Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof
CA2436739A1 (en) * 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
US7199124B2 (en) 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
ATE331519T1 (de) * 2001-05-16 2006-07-15 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
RS95003A (en) * 2001-05-31 2007-02-05 Sanofi-Aventis, Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
WO2002100433A1 (en) * 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
HUP0401949A3 (en) * 2001-10-22 2009-07-28 Mitsubishi Tanabe Pharma Corp 4-imidazolin-2-one derivatives
US7473695B2 (en) 2001-10-22 2009-01-06 Mitsubishi Tanabe Pharma Corporation 4-imidazolin-2-one compounds
US7064139B2 (en) * 2001-10-29 2006-06-20 Uniroyal Chemical Company, Inc. Method for treating retroviral infections
JP2005538975A (ja) * 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
WO2004005283A1 (en) * 2002-07-09 2004-01-15 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
WO2004018463A2 (en) * 2002-08-23 2004-03-04 Rigel Pharmaceuticals, Inc. Pyridyl substituted heterocycles useful for treating or preventing hcv infection
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
WO2004099165A2 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Heterocyclic compounds and hydro isomers thereof
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
EP3002283B1 (en) 2003-12-26 2017-06-14 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
JP2007223903A (ja) * 2004-07-09 2007-09-06 Takeda Chem Ind Ltd 新規な固体分散体およびその製造方法
JP4973191B2 (ja) * 2004-11-10 2012-07-11 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
JP2008540425A (ja) 2005-05-02 2008-11-20 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝可能部分を含む複素環式抗ウイルス性化合物およびその使用
WO2006137658A1 (en) * 2005-06-20 2006-12-28 Dongbu Hitek Co., Ltd. New substituted 1,3-thiazole derivatives or pharmaceutically acceptable salts thereof having immunosuppression and inflammation inhibitory acitivity, intermediate compounds or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and pharmaceutical composition comprising the same
US7494519B2 (en) * 2005-07-28 2009-02-24 3M Innovative Properties Company Abrasive agglomerate polishing method
DK1921077T3 (en) * 2005-08-02 2017-10-23 Kyowa Hakko Kirin Co Ltd Means for treating and / or preventing sleep disorders
WO2007022415A2 (en) * 2005-08-18 2007-02-22 Pharmacopeia, Inc. Substituted 2-aminothiazoles for treating neurodegenerative diseases
RU2008112691A (ru) * 2005-10-03 2009-10-10 Оно Фармасьютикал Ко., Лтд. (Jp) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
CA2627497C (en) 2005-10-28 2014-10-14 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
US20100227804A1 (en) * 2006-01-18 2010-09-09 The University Of Tokyo Gel-forming composition for medical use, administration device for the composition, and drug release controlling carrier
US20090192164A1 (en) * 2006-06-28 2009-07-30 Aska Pharmaceutical Co., Ltd. Treating agent of inflammatory bowel disease
EP2055268A4 (en) * 2006-08-21 2012-05-30 Next21 Kk BONE MODEL, BONE FILLER AND METHOD FOR PRODUCING THE BONE FILLER
ES2423929T3 (es) * 2007-02-16 2013-09-25 Aska Pharmaceutical Co., Ltd. Composición farmacéutica que contiene suspensión basada en aceite de partículas finas
JP5328643B2 (ja) 2007-04-20 2013-10-30 大同化成工業株式会社 新規乾式固体分散体用基剤、該基剤を含有する固体分散体及び該分散体を含有する組成物
EP2198710A1 (de) * 2008-12-19 2010-06-23 Bayer CropScience AG Verwendung von 5-Pyridin-4yl-(1,3)Thiazole zur Bekämpfung phytopathogener Pilze
US8900628B2 (en) 2010-02-26 2014-12-02 Nisshin Kasei Co., Ltd. Hard capsule and method for producing same
JP6225113B2 (ja) 2012-09-26 2017-11-01 武田薬品工業株式会社 固体粒子の製造方法
CN103288817A (zh) * 2013-07-02 2013-09-11 天津理工大学 一种基于1,3,4-噻二唑和1,3,4-噁二唑的希夫碱衍生物及其制备方法和应用
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
KR101851972B1 (ko) 2015-10-21 2018-06-11 주식회사 제이아이바이오팜 청호, 구절초, 애엽, 인진호, 괴각, 대계, 및 목향을 포함하는 한약 추출물이 함유된 탈모개선 및 탈모방지용 복합조성물 및 그 제조방법
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
CN108017584B (zh) * 2017-06-20 2021-03-23 南开大学 A3腺苷受体的小分子拮抗剂
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3128468A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0149884B1 (en) 1983-09-09 1992-12-16 Takeda Chemical Industries, Ltd. 5-pyridyl-1,3-thiazole derivatives, their production and use
JPH0570446A (ja) 1991-09-13 1993-03-23 Taisho Pharmaceut Co Ltd Ｎ−チアゾリルスルホンアミド誘導体
IL123950A (en) * 1995-10-06 2001-04-30 Merck & Co Inc Transformed imidazoles with anti-cancer and cytokine-inhibiting activity and pharmaceutical preparations containing them
MY128323A (en) 1996-09-30 2007-01-31 Otsuka Pharma Co Ltd Thiazole derivatives for inhibition of cytokine production and of cell adhesion
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6436966B1 (en) 1997-10-27 2002-08-20 Takeda Chemical Ind., Ltd. Adenosine A3 receptor antagonists
US7101899B1 (en) * 1999-04-23 2006-09-05 Takeda Pharmaceutical Company Limited 5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
WO2002100433A1 (en) * 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions

Also Published As

Publication number Publication date
KR100558123B1 (ko) 2006-03-07
CZ20013805A3 (cs) 2002-04-17
CN1156471C (zh) 2004-07-07
WO2000064894A1 (fr) 2000-11-02
EP1180518A1 (en) 2002-02-20
CA2370264A1 (en) 2000-11-02
ES2275500T3 (es) 2007-06-16
AU765473B2 (en) 2003-09-18
KR100449215B1 (ko) 2004-09-18
US20090048307A1 (en) 2009-02-19
MY126736A (en) 2006-10-31
PT1180518E (pt) 2007-02-28
US7101899B1 (en) 2006-09-05
DK1180518T3 (da) 2007-05-21
EP1180518A4 (en) 2004-09-15
SK14952001A3 (sk) 2002-04-04
HK1044338A1 (en) 2002-10-18
US20060135566A1 (en) 2006-06-22
NO320588B1 (no) 2005-12-27
PL351148A1 (en) 2003-03-24
HK1044338B (zh) 2007-06-29
BR0009952A (pt) 2002-03-26
US7276527B2 (en) 2007-10-02
NZ515215A (en) 2003-07-25
CZ300709B6 (cs) 2009-07-22
IL146105A0 (en) 2002-07-25
SI1180518T1 (sl) 2007-06-30
NO20015156D0 (no) 2001-10-22
EP1180518B1 (en) 2007-01-17
KR20020059453A (ko) 2002-07-12
RU2237062C2 (ru) 2004-09-27
CN1353710A (zh) 2002-06-12
MXPA01010675A (es) 2002-06-04
NO20015156L (no) 2001-12-18
AU3840100A (en) 2000-11-10
HUP0203766A2 (hu) 2003-03-28
DE60033028T2 (de) 2007-11-15
KR20010111314A (ko) 2001-12-17
HUP0203766A3 (en) 2008-01-28
SK286666B6 (sk) 2009-03-05
DE60033028D1 (de) 2007-03-08

Similar Documents

Publication Publication Date Title
IL146105A (en) 5-pyridyl-1, 3-azole compounds, process for producing the same and use therefor
TWI315741B (en) A-isomaltosyltransferase, process for producing the same and use thereof
AU2856499A (en) Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same
HUP0101192A3 (en) Cycloalkene derivatives, process for producing the same, and use
EP1223163A4 (en) PROCESS FOR PRODUCTION OF ACRYLONITRILE, CATALYST USAGE AND METHOD OF PREPARATION THEREOF
EP1223162A4 (en) A METHOD FOR THE PRODUCTION OF ACRYLONITRILE, A CATALYST FOR THIS USE AND A METHOD FOR THE PRODUCTION THEREOF
AU2001294228A1 (en) Benzimidazole compounds, process for producing the same and use thereof
ZA200300743B (en) DDS compound and process for the preparation thereof.
AU1306601A (en) Chemically modified supports and process for producing the same
PL351616A1 (en) Polyolefin compositions, method for the production and use thereof
IL139023A0 (en) Process for the preparation of 2,3,5-trimethyl-p- benzoquinone
GB9905512D0 (en) Process
GB9908814D0 (en) Process
AU2796602A (en) Coniosetin and derivatives thereof, method for producing the same and use thereof
GB9904162D0 (en) Process
HUP0105166A3 (en) Substances wk-5344a and wk-5344b and process for producing the same
HK1036519A1 (en) Voltage-nonlinear resistance and process for producing the same.
GB9914600D0 (en) Novel,process
GB9905418D0 (en) Process
HU0000208D0 (en) Process producing the secondary-alkoxy-1-alkenes
GB9903087D0 (en) Process
HU9901547D0 (en) Process for producing n,n-dimethyl-cyclohexyl-amine
AU4951000A (en) Microliposomes and process for producing the same
AU2002221114A1 (en) Novel ss-lactam compounds and process for preparing the same
EP1295940A4 (en) POLYPEPTIDES, THE APPLICATION THEREOF AND METHOD FOR THE PRODUCTION THEREOF

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed